85 related articles for article (PubMed ID: 6512580)
1. Alternating combination chemotherapy for stages III and IV ovarian carcinoma.
Young JA; Johnson A; Kroener J; Koziol JA; Saltzstein S; Yon JL; Campbell TN; Lucas W; Green MR
J Clin Oncol; 1984 Dec; 2(12):1317-20. PubMed ID: 6512580
[TBL] [Abstract][Full Text] [Related]
2. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
4. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
8. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
[TBL] [Abstract][Full Text] [Related]
10. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
11. Five-year survival for cisplatin-based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery.
River MS; Fanning J; Sprance HE
J Surg Oncol; 1991 Sep; 48(1):39-44. PubMed ID: 1890837
[TBL] [Abstract][Full Text] [Related]
12. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
[TBL] [Abstract][Full Text] [Related]
13. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644
[TBL] [Abstract][Full Text] [Related]
14. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
15. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
[TBL] [Abstract][Full Text] [Related]
16. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
Coleman M; Pasmantier MW; Silver RT
Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
[TBL] [Abstract][Full Text] [Related]
17. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
[TBL] [Abstract][Full Text] [Related]
18. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.
Daniels JR; Chak LY; Sikic BI; Lockbaum P; Kohler M; Carter SK; Reynolds R; Bohnen R; Gandara D; Yu J
J Clin Oncol; 1984 Nov; 2(11):1192-9. PubMed ID: 6092554
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of advanced ovarian cancer. Göttingen-Hannover studies].
Kühnle H; Hilfrich J
Onkologie; 1985 Dec; 8(6):374-82. PubMed ID: 3912694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
